INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

25 6 2024 15:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

17 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Names Brian Goff to its Board of Directors

14 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

02 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

09 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

02 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

29 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

26 4 2024 09:47:12 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

25 4 2024 09:45:07 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

19 4 2024 09:45:17 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

18 4 2024 09:45:05 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

17 4 2024 09:45:39 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

16 4 2024 09:45:16 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

15 4 2024 14:45:30 提供 NetDania Notify

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

18 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

22 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

15 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

14 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

31 1 2024 17:00:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

04 1 2024 16:01:00 提供 Nasdaq GlobeNewswire